Relative survival benefit and morbidity with fluids in severe sepsis - A network meta-analysis of alternative therapies

Current Clinical Pharmacology

Volumn 8, Issue 4, 2013, Pages 236-245

  Bansal, M ^a   Farrugia, A ^a,b   Balboni, S ^a   Martin, G ^c  

^a Plasma Protein Therapeutics Association   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Albumin; Crystalloid; Hydroxyethyl starch; Meta analysis; Resuscitation; Sepsis; Septic shock; Severe sepsis

Indexed keywords

ALBUMIN; HETASTARCH; ANTIFIBRINOLYTIC AGENT;

ALTERNATIVE MEDICINE; ARTICLE; BAYES THEOREM; CRYSTALLOID; DISEASE SEVERITY; FLUID RESUSCITATION; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SURVIVAL; SYSTEMATIC REVIEW; ANALGESIA; BLEEDING; BLOOD TRANSFUSION; COLLOID; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CRITICALLY ILL PATIENT; DATA BASE; DIABETIC NEUROPATHY; FLUID THERAPY; FOLLOW UP; HEART SURGERY; HYPOTENSION; MALARIA; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRURITUS; REVIEW; RISK FACTOR; THERAPY EFFECT;

ALBUMINS; BAYES THEOREM; FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; INTENSIVE CARE UNITS; ISOTONIC SOLUTIONS; RENAL REPLACEMENT THERAPY; RISK; SEPSIS; SURVIVAL ANALYSIS;

EID: 84888091948     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748863113089990046     Document Type: Article

References (67)

1. Dellinger RP, Levy M, Rhodes A, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41(1): 580-637.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29(7): 1303-10.
3. Dellinger RP. Cardiovascular management of septic shock. Crit Care Med 2003; 31(3): 946-55.
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348(16): 1546-54.
5. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004; 8(4): 222-6.
6. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35(5): 1244-50.
7. Healthcare Cost and Utilization Project (HCUP). HCUP Nationwide Inpatient Sample (NIS) [Internet]. Rockville, MD.: Agency for Healthcare Research and Quality; 2010. Available from: http://hcupnet. ahrq. gov.
8. Keith Berman. Albumin 2015: A Market Profile and Forecast of Albumin in the United States through the year 2015. USA: The Marketing Research Bureau Inc.; 2011 Jun.
9. Finfer S, Liu B, Taylor C, et al. Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care 2010; 14: R185.
10. Farrugia A. Albumin usage in clinical medicine: tradition or therapeutic? Transf Med Rev 2010; 24(1): 53-63.
11. Finfer S, Bellomo R, McEvoy S, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ 2006; 18: 333(7577): 1044.
12. Quinlan GJ, Margarson MP, Mumby S, et al. Administration of albumin to patients with sepsis syndrome: A possible beneficial role in plasma thiol repletion. Clin Sci 1998; 95: 459-65.
13. Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011; 364(26): 2483-95.
14. Mira JP. Facts or myths: Early albumin resuscitation during septic shock (the EARSS trial) [Internet]. Berlin; 2011 [cited 2013 Jun 17]. Available from: http://www. esicm. org/flashConference/2011/Berlin/10438/swf/player. swf.
15. Guidet B, Martinet O, Boulain T, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0. 4 versus 0. 9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care 2012; 16(R94): 1-33.
16. Perner A. 6S Trial Group and the Scandinavian Critical Care Trials Group. Hydroxyethyl Starch 130/0. 4 versus Ringer's Acetate in Severe Sepsis. N Engl J Med 2012; 367(5): 481.
17. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care. N Engl J Med 2012; 367(20): 1901-11.
18. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S. Fluid resuscitation with 6 % hydroxyethyl starch (130/0. 4 and 130/0. 42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 2013; 9(4): 782-3.
19. Haase N, Perner A, Hennings LI, et al, Hydroxyethyl starch 130/0. 38-0. 45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013; 346: f839.
20. Zarychanski R, Abou-Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013; 309(7): 678-88.
21. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2012; 6: CD000567.
22. Patel A, Waheed U, Brett SJ. Randomised trials of 6 % tetrastarch (hydroxyethyl starch 130/0. 4 or 0. 42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med 2013; 39(5): 811-22.
23. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: A systematic review and meta-analysis. Crit Care Med 2011; 39(2): 386-91.
24. Jansen JP, Fleurence R, Devine B, et al. Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Val in Health 2011; 14(4): 417-28.
25. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331(7521): 897-900.
26. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials. Tech Supp Doc Ser 2011; (4): 1-98.
27. Veneman TF, Nijhuis JO, Woittiez AJJ. Human albumin and starch administration in critically ill patients: a prospective randomized clinical trial. Wiener klinische Wochenschrift 2004; 116(9): 305-9.
28. Rackow E, Falk J, Fein I. Fluid resuscitation in circulatory shock: A comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 1983; 11: 839-50.
29. Dias S, Welton N, Sutton A, Ades A. NICE DSU Technical Support Document 2: A Generalized Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials [Internet]. National Institute for Health and Clinical Excellence (NICE); 2012 Apr. Available from: http://www. nicedsu. org. uk/TSD2%20General%20meta%20analysi s%20corrected%20Mar2013. pdf.
30. Zarychanski R, Turgeon AF, Fergusson DA, et al. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 2009; 3(4): e196.
31. Gattinoni L. Albumin in septic shock: The ALBIOS study. Lisbon; 2012 [cited 2013 Jun 19]. Available from: http://www. albuminppta. com/-sepsis-literature-database/304-albumin-administrationimproves-survival-in-severe-sepsis-and-septic-shock-the-albiosstudy.
32. Juni P, Altman D, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001; (323): 42-6.
33. Andrew Thomas. OpenBUGS 3. 2. 1 (Bayesian inference Using Gibbs Sampling). http://www. openbugs. info/w/.
34. Lu G, Ades AE. Assessing Evidence Inconsistency in Mixed Treatment Comparisons. J Am Stat Assoc 2006; 101(474): 447-59.
35. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med 2002; 21(11): 1601-23.
36. Rasmussen LS, Yentis SM, Van Aken H, et al. Editors-in-Chief statement regarding published clinical trials conducted without IRB approval by Joachim Boldt. Minerva Anestesiol. 2011; 77(5): 562-3.
37. Dias S, Sutton A, Welton N, Ades A. NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-Regression, Bias and Bias-Adjustment. National Institute for Health and Clinical Excellence (NICE); 2012 Apr. http://www. nicedsu. org. uk.
38. Naci H, Brugts JJ, Fleurence R, Ades A. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256, 827 individuals in 181 randomized controlled trials. Eur J Prev Cardiol 2013; 20(4): 658-70.
39. Farrugia A. Safety of plasma volume expanders. J Clin Pharmacol 2011; 51(3): 292-300.
40. Food and Drug Administartion. Risks and Benefits of Hydroxyethyl Starch Solutions. Bethesda, Maryland; 2012 [cited 2013 Jan 29]. http://www. fda. gov/downloads/BiologicsBloodVacc ines/NewsEvents/WorkshopsMeetingsConferences/UCM321588. p df.
41. Dolecek M, Svoboda P, Kantorova' I. Therapeutic influence of 20% albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: A randomized controlled trial. Hepatogastroenterology 2009; 56: 1622-8.
42. Maitland K, Pamba A, English M, et al. Pre-transfusion management of children with severe malarial anaemia: a randomised controlled trial of intravascular volume expansion. Brit J Haematol 2005; 128(3): 393-400.
43. Maitland K, Pamba A, English M, et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis 2005; 40(4): 538-45.
44. Maitland K, Marsh K. Pathophysiology of severe malaria in children. Acta Trop 2004; 90(2): 131-40.
45. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358(2): 125-39.
46. McIntyre LA, Fergusson D, Cook D, Rankin N, Dhingra V, Granton J. Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trial. Can J Anaesth 2008; 55(12): 819-26.
47. Patel A, Waheed U, Brett SJ. Randomised trials of 6 % tetrastarch (hydroxyethyl starch 130/0. 4 or 0. 42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Medicine 2013; 39(5): 811-22.
48. Griebeler ML, Tsapas A, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network metaanalysis (Protocol). Syst Rev 2012; 1: 61.
49. Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A. Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies. BMJ 2012; 345: e5798.
50. Salanti Georgia. The use of network meta-analysis in Cochrane reviews: concerns and future directions [Internet]. Auckland, New Zealand; 2012 [cited 2013 Feb 28]. http://www. mtm. uoi. gr/PLE NARY. pdf.
51. Dundar Y, Dodd S, Williamson P, Dickson R, Walley T. Case study of the comparison of data from conference abstracts and fulltext articles in health technology assessment of rapidly evolving technologies: does it make a difference? Int J Technol Assess Health Care 2006; 22(3): 288-94.
52. Akech S, Gwer S, Idro R, et al. Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin Trials 2006; 1(5): e21.
53. Wolf M, Kronenberg H, Dodds A, et al. A safety study of Albumex 5, a human albumin solution produced by ion exchange chromatography. Vox Sang 1996; 70(4): 198-202.
54. Westphal M, James M, Kozek-Langenecker S, Stocker R, Giuidet B, Aken H. Hydroxyethyl Starches. Different Products-Different Effects. Anesthesiology 2009; 111: 187-202.
55. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. The Cochrane Collaboration, Dart AB, editors. Cochrane Database of Syst Rev 2010 Jan 20 [cited 2012 Jun 27]; http://doi. wiley. com/10. 1002/14651858. CD007594. pub2.
56. European Medicines Agency. PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch. 2013 [cited 2013 Jun 18]. http://www. ema. europa. eu/ema/index. jsp? curl=pages/medicines/human/referrals/Hydroxyethy l_starch-containing_solutions/human_referral_prac_000012. jsp&m id=WC0b01ac05805c516f.
57. Reid F, Lobo DN, Williams RN, Rowlands BJ, Allison SP. (Ab)normal saline and physiological Hartmann's solution: a randomized double-blind crossover study. Clin Sci 2003; 104(1): 17-24.
58. Burdett E, Dushianthan A, Bennett-Guerrero E, et al. Perioperative buffered versus non-buffered fluid administration for surgery in adults. Cochrane Database Syst Rev 2012; 12: CD004089.
59. Bellmann R, Feistritzer C, Wiedermann CJ. Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies. Clin Pharmacokinet 2012; 51(4): 225-36.
60. Christidis C, Mal F, Ramos J, et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001; 35(6): 726-32.
61. Schmidt-Hieber M, Loddenkemper C, Schwartz S, Arntz G, Thiel E, Notter M. Hydrops lysosomalis generalisatus--an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol. 2006; 77(1): 83-5.
62. Baxter Healthcare Corporation A. BUMINATE 5%, Albumin (Human), USP, 5% Solution-Prescribing Information. 2009 Sep [cited 2012 Dec 13]; http://www. 4legpharma. com/Product%20Inse rt s/Baxter/Buminate5_9-2009. pdf.
63. Baxter Healthcare Corporation. BUMINATE 25%, Albumin (Human), USP, 25% Solution-Prescribing Information. 2009 Sep [cited 2012 Dec 13]; http://www. homebybaxter. us/downloads/healt hcare_professionals/products/Buminate_25_PI. pdf.
64. US Food and Drug Administration. Approved Product Information for Voluven. 2012 [cited 2012 Aug 31]. http://www. fda. gov/downl oads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProd ucts/NewDrugApplicationsNDAs/UCM083138. pdf.
65. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Australian Government, Department of Health and Ageing; 2008 Dec.
66. Wells G, Sultan S, Chen L, Khan M, Coyle D. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. Canadian Agency for Drugs and Technologies in Health; 2009.
67. Lu G, Ades A. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-24.